Current aspects of biology, risk assessment, and treatment of neuroblastoma

Seminars in Surgical Oncology

Volumn 16, Issue 2, 1999, Pages 91-104

  Haase, Gerald M ^a,c   Perez, Carlos ^b   Atkinson, James B ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Biological tumor markers; Chromosome abnormalities; Combined antineoplastic agents; Combined modality therapy; Differential diagnosis; Gene amplification; Horner's syndrome; Infant; Iodine radioisotopes; Magnetic resonance imaging; Myc genes; Myoclonus; Neoplasm metastasis; Neoplasm staging; Neoplasms classification; Neuroblastoma; Neurofibromatosis 1; Newborn infant; Ocular motility disorders; Prognosis; Risk factors; Spontaneous remission; Translocation; X ray computed tomography

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; IFOSFAMIDE; MELPHALAN; TOPOTECAN;

ARTICLE; CANCER RISK; CANCER STAGING; CHILD; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GENETIC DISORDER; HIGH RISK POPULATION; HORNER SYNDROME; HUMAN; INFANT; NEUROBLASTOMA; NEUROFIBROMATOSIS; NEWBORN; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT PLANNING;

ADOLESCENT; ALGORITHMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM STAGING; NEUROBLASTOMA;

EID: 0032961066     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199903)16:2<91::AID-SSU3>3.0.CO;2-1     Document Type: Article

References (166)

1. Reynolds CP, Seeger RC: Neuroblastoma. In Haskell CM, Berek JS (eds): "Cancer treatment." 4th ed. Philadelphia:WB Saunders; 1995. p. 860-871.
2. Miller RW, Young JL Jr, Novakovic B: Childhood cancer. Cancer 1995;75(1 Suppl):395-405.
3. Carlsen NL: Why age has independent prognostic significance in neuroblastomas. Evidence for intra-uterine development, and implications for the treatment of the disease. Anticancer Res 1988;8:255-262.
4. Carlsen NL: Neuroblastomas presenting in the first year of life: epidemiological differences from those presenting at older ages. Cancer Detect Prev 1996;20:251-261.
5. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-416.
6. Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group. Hum Pathol 1988;19:1187-1198.
7. Shimada H, Stram DO, Chatten J, et al: Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87:1470-1476.
8. Meitar D, Crawford SE, Rademaker AW, Cohn SL: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-414.
9. Suzuki T, Yokota J, Mugishima H, et al: Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 1989;49:1095-1098.
10. Srivatsan ES, Murali V, Seeger RC: Loss of heterozygosity for alleles on chromosomes 11q and 14q in neuroblastoma. Prog Clin Biol Res 1991;366:91-98.
11. Srivatsan ES, Ying KL, Seeger RC: Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer 1993;7:32-37.
12. Caron H, van Sluis P, van Roy N, et al: Recurrent 1; 17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 1994;5:341-347.
13. Van Roy N, Laureys G, Cheng NC, et al: 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994;10:103-114.
14. Schleiermacher G, Delattre O, Peter M, et al: Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: a single-institution study. Int J Cancer 1996;69:73-78.
15. Maris JM, White PS, Beltinger CP, et al: Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995;55:4664-4669.
16. Caron H, van Sluis P, de Kraker J, et al: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-230.
17. Fong CT, White PS, Peterson K, et al: Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992;52:1780-1785.
18. Brodeur GM: Neuroblastoma - clinical applications of molecular parameters [Review]. Brain Pathol 1990;1:47-54.
19. Plantaz D, Mohapatra G, Matthay KK, et al: Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 1997;150:81-89.
20. Look AT, Haves FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-235.
21. Taylor SR, Blatt J, Constantino JP, et al: Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer 1988;62:749-754.
22. Cohn SL, Rademaker AW, Salwen HR, et al: Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 1990;136:1043-1052.
23. Naito M, Iwafuchi M, Ohsawa Y, et al: Flow cytometric DNA analysis of neuroblastoma: prognostic significance of DNA ploidy in unfavorable group. J Pediatr Surg 1991;26:834-837.
24. Gansler T, Chatten J, Varello M, et al: Flow cytometric DNA analysis of neuroblastoma: correlation with histology and clinical outcome. Cancer 1986;58:2453-2458.
25. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-591.
26. Bowman LC, Castleberry RP, Cantor A, et al: Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997;89:373-380.
27. Hayashi Y, Inaba T, Hanada R, Yamamoto K: Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening. J Pediatr 1988;112:567-571.
28. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224(4654):1121-1124.
29. Seeger RC, Wada R, Brodeur GM, et al: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 1988;271:41-49.
30. Nisen PD, Waber PG, Rich MA, et al: N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988;80:1633-1637.
31. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the Nmyc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
32. Brodeur GM, Seeger RC, Sather H, et al: Clinical implications of oncogene activation in human neuroblastomas. Cancer 1986; 58:541-545.
33. Brodeur GM, Fong CT: Molecular biology and genetic of human neuroblastoma. Cancer Genet Cytogenet 1989;41:153-174.
34. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996;14:2417-2426.
35. Matthay KK, Strain D, Reynolds CP, et al: Multivariate analysis of prognostic factors in 36 children with stage IV neuroblastoma: a Children's Cancer Group (CCG) study [Abstract]. Med Pediatr Oncol 1997;29:411.
36. Bourhis J, DeVathaire F, Wilson GD, et al: Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991;51:33-36.
37. Brodeur GM, Hayes FA, Green M, et al: Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987; 47:4248-4253.
38. Kim CJ, Lee YA, Ahn HS, et al: An immunohistochemical analysis of mdr-1 and bcl-2 expressions in neuroblastoma. Pathol Res Pract 1995;191:1010-1015.
39. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death [Review]. Blood 1992;80:879-886.
40. Ikeda H, Hirato J, Akami M, et al: Massive apoptosis detected by in situ DNA nick end labeling in neuroblastoma. Am J Surg Pathol 1996;20:649-655.
41. Dole M, Nunez G, Merchant AK, et al: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994; 54:3253-3259.
42. Bordow SB, Haber M, Madafiglio J, et al: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994;54:5036-5040.
43. Norris MD, Bordow SB, Marshall GM, et al: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334: 231-238.
44. Matsushima H, Bogenmann E: Expression of trkA cDNA in neuroblastoma mediates differentiation in vitro and in vivo. Mol Cell Biol 1993;13:7447-7456.
45. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: High expression of the TRK gene in human neuroblastoma is associated with favorable outcome: possible role of tumor differentiation and regression. N Eng J Med 1993;328:847-854.
46. Nakagawara A, Arima M, Azar C, et al: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-1368.
47. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993;85:377-384.
48. Scala S, Wosikowski K, Giannakakou P, et al: Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 1996;56:3737-3742.
49. Ryden M, Sehgal R, Dominici C, et al: Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 1996; 74:773-779.
50. Berthold F, Engelhardt-Fahrner U, Schneider A, et al: Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma. In Vivo 1991;5:245-247.
51. Hann HW, Evans AE, Siegel SE, et al: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma. The Children's Cancer Study Group Experience. Cancer Res 1985;45:2843-2848.
52. Joshi VV, Cantor AB, Brodeur GM, et al: Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer 1993;71:3173-3181.
53. Schulz G, Cheresh DA, Varki NM, et al: Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914-5920.
54. Valentino L, Moss T, Olson E, et al: Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990;75:1564-1567.
55. Rascher W, Kremens B, Wagner S, et al: Serial measurements of neuropeptide Y in plasma for monitoring neuroblastoma in children. J Pediatr 1993;122:914-916.
56. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT: Chromogranin A in children with neuroblastoma. J Clin Invest 1990;85:1555-1559.
57. Gaetano C, Manni I, Bossi G, et al: Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. Eur J Cancer 1995; 31A:447-452.
58. Hiyama E, Hiyama K, Yokoyama T, et al: Telomerase activity in human neuroblastoma [Abstract]. Proc Annu Meet Am Assoc Cancer Res 1995;36:A3301.
59. Gross N, Beretta C, Peruisseau G, et al: CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 1994;54:4238-4242.
60. Combaret V, Lasset C, Frappaz D, et al: Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Eur J Cancer 1995;31A:545-549.
61. Kawasaki H, Mukai K, Yajima S, et al: Prognostic value of proliferating cell nuclear antigen (PCNA) immunostaining in neuroblastoma. Med Ped Onc 1995;24:300-304.
62. Smith EI, Castleberry RP: Neuroblastoma [Review]. Curr Prob Surg 1990;27:573-620.
63. Rosen EM, Cassady JR, Frantz CN, et al: Neuroblastoma: The Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/ Children's Hospital experience. J Clin Oncol 1984;2:719-732.
64. Weinblatt ME, Heisel MA, Siegel SE: Hypertension in children with neurogenic tumors. Pediatrics 1983;71:947-951.
65. Bertani-Dziedzic L, Dziedzic SW, Gitlow SE: Catecholamine metabolism in neuroblastoma. In Pochedly C (ed): "Neuroblastoma: tumor biology and therapy". Boca Raton, FL:CRC; 1990. p. 69-91.
66. Bohdiewicz PJ, Gallegos E, Fink-Bennett D: Raccoon eyes and the MIBG super scan: scintigraphic signs of neuroblastoma in a case of suspected child abuse. Pediatr Radiol 1995;25Suppl 1:S90-92.
67. Altman AJ, Baehner RL: Favorable prognosis for survival in children with coincident opsomyoclonus and neuroblastoma. Cancer 1976;37:846-852.
68. Fisher PG, Wechsler DS, Singer HS: Anti-Hu antibody in a neuroblastoma associated paraneoplastic syndrome. Pediatr Neurol 1994;10:309-312.
69. Roberts KB, Freeman JM: Cerebellar ataxis and "occult neuroblastoma" without opsoclonus. Pediatrics 1975;56:464-465.
70. Mitchell WG, Snodgrass SR: Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol 1990;5:153-158.
71. Mendelsohn G, Eggleston JC, Olson JL, et al: Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors. Lab Invest 1979;41:144-149.
72. Kaplan SJ, Holbrook CT, McDaniel HG, et al: Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child 1980;134:21-24.
73. Gibbs J, Appleton RE, Martin J, Findlay G: Congenital Horner syndrome associated with non-cervical neuroblastoma. Dev Med Child Neurol 1992;34:642-644.
74. Bolande RP, Towler WF: A possible relationship of neuroblastoma to von Recklinghausen's disease. Cancer 1970;26:162-175.
75. Kushner BH, Hajdu SL, Helson L: Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature. J Clin Oncol 1985;3:117-120.
76. Bellah R, D'Andrea A, Darillis E, Fellows KE: The association of congenital neuroblastoma and congenital heart disease. Is there a common embryologic basis? Pediatr Radiol 1989;19:119-121.
77. Sirinelli D, Silberman B, Baudon JJ, et al: Beckwith-Wiedemann syndrome and neural crest tumors. A report of two cases. Pediatr Radiol 1989;19:242-245.
78. Patrone PM, Chatten J, Weinberg P: Neuroblastoma and DiGeorge anomaly. Pediatr Pathol 1990;10:425-430.
79. Stovroff M, Dykes F, Teague WG: The complete spectrum of neurocristopathy in an infant with congenital hypoventilation, Hirschsprung's disease, and neuroblastoma. J Pediatr Surg 1995;30:1218-1221.
80. Triche TJ, Askin FB, Kissane JM: Neuroblastoma, Ewing's sarcoma, and the differential diagnosis of small-, round-, blue-cell tumors. In Finegold M (ed): "Pathology of neoplasia in children and adolescents". Philadelphia: WB Saunders; 1986. p. 145.
81. Dehner LP: Pathologic anatomy of classic neuroblastoma: Including prognostic features and differential diagnosis. In Pochedly C (ed): "Neuroblastoma: tumor biology and therapy". Boca Raton, FL:CRC Press; 1990. p. 111-143.
82. Triche TJ: Neuroblastoma and other childhood neural tumors: a review [Review]. Pediatr Pathol 1990;10:175-193.
83. Brodeur GM, Pritchard J, Berthold F, et al: Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
84. Hayes FA, Green AA, Rao BN: Clinical manifestations of ganglioneuroma. Cancer 1989;63:1211-1214.
85. Laug WE, Siegel SE, Shaw KNF, et al: Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978;62:77-83.
86. Graham-Pole J, Salmi T, Anton AH, et al: Tumor and urine catecholamines (CATS) in neurogenic tumors. Correlations with other prognostic factors and survival. Cancer 1983;51:834-839.
87. Nishi M, Miyake H, Takeda T, et al: Can a patient with neuroblastoma be diagnosed by a single urine sample collected randomly? Oncology 1991:48:31-33.
88. Seltzer PM, Marangos PJ, Evans AE, et al: Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 1986;57:1230-1234.
89. Berthold F, Treehow R, Utsch S, Zieschang J: Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol 1992;14:207-215.
90. Hann HW, Evans AE, Cohen IJ, Leitmeyer JE: Biologic differences between neuroblastoma stage IVS and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med 1981;305:425-429.
91. Shuster JJ, McWilliams NB, Castleberry R, et al: Serum lactate dehydrogenase in childhood neuroblastoma. Am J Clin Oncol 1992;15:295-303.
92. MacDonald WB, Stevens MM, Dalla Pozza L, et al: Gallium-67 and technetium-99m-methylene diphosphonate skeletal scintigraphy in determining prognosis for children with stage IV neuroblastoma. J Nucl Med 1993;34:1082-1086.
93. Berdon WE, Ruzal-Shapiro C, Abramson SJ, et al: The diagnosis of abdominal neuroblastoma: relative roles of ultrasonography, CT, and MRI. Urol Radiol 1992;14:252-262.
94. Toma P, Lucigrai G, Marzoli A, et al: Prenatal diagnosis of metastatic adrenal neuroblastoma with sonography and MR imaging. AJR. Am J Roentgenol 1994;162:1183-1184.
95. Ng YY, Kingston JE: Review: The role of radiology in the staging of neuroblastoma. Clin Radiol 1993:47:226-235.
96. Dietrich RB, Kangarloo H, Lenarsky C, Feig SA: Neuroblastoma: the role of MR imaging. AJR. Am J Roentgenol 1987;148: 937-942.
97. Kornreich L, Horev G, Kaplinsky C, et al: Neuroblastoma: evaluation with contrast enhanced MR imaging. Pediatr Radiol 1991;21:566-569.
98. Wang YM, Li YW, Sheih CP, et al: Magnetic resonance imaging of neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Acta Paediatr Sin 1995;36:420-424.
99. Jacobs A, Delree M, Desprechins B, et al: Consolidating the role of *I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol 1990;20:157-159.
100. Andrich MP, Shalaby-Rana E, Novassaghi N, et al: The role of 131 iodine metaiodobenzylguanidine scanning in the correlative imaging of patients with neuroblastoma. Pediatrics 1996;97: 246-250.
101. Suc A, Lumbroso J, Rubie H, et al: Metastatic neuroblastoma in children older than one year. Cancer 1996;77:805-811.
102. Martinez DA, O'Dorisio MS, O'Dorisio TM, et al: Intraoperative detection and resection of occult neuroblastoma: a technique exploiting somatostatin receptor expression. J Pediatr Surg 1995; 30:1580-1589.
103. Shulkin BL, Hutchinson RJ, Castle VP, et al: Neuroblastoma: positron emission tomography with 2-[Fluorine-18]-Fluoro-2-deoxy-D-glucose compared with Metaoidobenzylguanidine scintigraphy. Radiology 1996;199:743-750.
104. Reid MM, Roald B: Adequacy of bone marrow trephine biopsy specimens in children. J Clin Pathol 1996;49:226-229.
105. Smith MB, Katz R, Black CT, et al: A rational approach to the use of fine needle aspiration biopsy in the evaluation of primary and recurrent neoplasms in children. J Pediatr Surg 1993;28:1245-1247.
106. Hoffer FA, Chung T, Diller L, et al: Percutaneous biopsy for prognostic testing of neuroblastoma. Radiology 1996;200:213-216.
107. Haase GM: Staging systems for neuroblastoma: a look at the old and the new. Pediatr Surg Int 1991;6:14-18.
108. Evans EA, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. Cancer 1971;27:374-378.
109. Carlsen NL, Christensen IJ, Schroeder H, et al: Prognostic value of different staging systems in neuroblastomas and completeness of tumour excision. Arch Dis Child 1986;61:832-842.
110. Evans AE, D'Angio GJ, Sather HN, et al: A comparison of four staging systems for localized and regional neuroblastoma: a report from the Children's Cancer Study Group. J Clin Oncol 1990; 8:678-688.
111. Hayes FA, Green A, Husto HO, Kumar M: Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases. J Pediatr 1983;102:59-62.
112. Ninane J, Pritchard J, Morris Jones PH, et al: Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement. Arch Dis Child 1982;57:438-442.
113. Le Tourneau JN, Bernard JL, Hendren WH, et al: Evaluation of the role of surgery in 130 patients with neuroblastoma. J Pediatr Surg 1985;20:244-249.
114. Nitschke R, Smith EI, Shochat S, et al: Localized neuroblastoma treated by surgery. A Pediatric Oncology Group study. J Clin Oncol 1988;6:1271-1279.
115. Nephroblastoma. In Hermanek P, Sobin LH (eds): "TNM classification of malignant tumors". 4th ed. New York: Springer; 1987. p. 188-192.
116. rd ed. American Joint Committee on Cancer. Philadelphia:Lippincott; 1988. p. 275-276.
117. Hata Y, Naito H, Sasaki F, et al: Fifteen years' experience of neuroblastoma: a prognostic evaluation according to the Evans and UIC staging systems. J Pediatr Surg 1990;25:326-329.
118. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-1881.
119. Smith EI, Haase GM, Seeger RC, et al: A surgical perspective on the current staging in neuroblastoma - the International Neuroblastoma Staging System protocol. J Pediatr Surg 1989;24:386-390.
120. Haase GM, Atkinson JB, Stram DO, et al: Surgical management and outcome of locoregional neuroblastoma: comparison of the Children's Cancer Group and the International Staging System. J Pediatr Surg 1995;30:289-295.
121. Matthay KK: Neuroblastoma: a clinical challenge and a biologic puzzle [Review]. CA Cancer J Clin 1995;45:179-192.
122. Castleberry RP, Strother DR, Bowman LC, et al: The development of risk-related therapy for neuroblastoma: the Pediatric Oncology Group (POG) experience. Proc Am Assoc Cancer Res 1996;37:659-660.
123. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas [Review]. Eur J Cancer 1995;31A:505-510.
124. Haase GM, Wong KY, de Lorimier AA, et al: Improvement in survival after excision of primary tumor in stage III neuroblastoma. J Pediatr Surg 1989;24:194-200.
125. Shorter NA, Davidoff AM, Evans AE, et al: The role of surgery in the management of stage IV neuroblastoma: a single institution study. Med Pediatr Oncol 1995;24:287-291.
126. Chamberlain RS, Quinones R, Dinndorf P, et al: Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma. Ann Surg Oncol 1996;2:93-100.
127. Ungerleider RS: Working conference on neuroblastoma treatment trials. Cancer Treat Rep 1981;65:719-723.
128. Evans AE, Baum E, Chard R: Do infants with stage IV-S neuroblastoma need treatment? Arch Dis Child 1981;56:271-274.
129. Nickersen HJ, Nesbit ME, Grosfeld JL, et al: Comparison of stage IV and IV-S neuroblastoma in the first year of life. Med Pediatr Oncol 1985;13:261-268.
130. Evans AE, Chatten J, D'Angio GJ, et al: A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. Cancer 1980;45:833-839.
131. Haas D, Ablin AR, Miller C, et al: Complete pathologic maturation and regression of stage IV-S neuroblastoma without treatment. Cancer 1988;62:818-825.
132. Martinez DA, King DR, Ginn-Pease ME, et al: Resection of the primary tumor is appropriate for children with stage IV-S neuroblastoma: an analysis of 37 patients. J Pediatr Surg 1992;27:1016-1022.
133. Strother D, Shuster JJ, McWilliams N, et al: Results of Pediatric Oncology Group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 1995;17:254-259.
134. Ninane J, Pritchard J, Malpas JS: Chemotherapy of advanced neuroblastoma: does adriamycin contribute? Arch Dis Child 1981; 56:544-548.
135. Shafford EA, Rogers DW, Pritchard J. Advanced neuroblastoma: improved response rate using a multi-agent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 1984; 2:742-747.
136. Castleberry RP, Kun LE, Shuster G, et al: Radiotherapy improves the outlook for patients older than 1 year with Paediatric Oncology Group stage C neuroblastoma. J Clin Oncol 1991;9:789-795.
137. Graham-Pole J, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:152-158.
138. August CS, Serota FT, Koch PA, et al: Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation and allogeneic or autologous marrow reconstitution. J Clin Oncol 1984; 2:609-616.
139. Punt N, Pritchard J, Pincott J, et al: Neuroblastoma: a review of 21 cases presenting with spinal cord compression. Cancer 1980; 45:3095-3101.
140. Halperin E: Neuroblastoma. In Halperin EC, Kun L, Constine L, Tarbell N (eds): "Pediatric radiation oncology". New York: Raven Press; 1989. p. 134-160.
141. Matthay KK, Sather HN, Seeger RC, et al: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989;7:236-244.
142. Matthay KK, Stram D, Seeger RC, et al: A prospective Children's Cancer Group study of stage II neuroblastoma. Proc Am Soc Clin Oncol 1993;12:414.
143. Hayes FA, Green AA, Casper J, et al: Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. Cancer 1981;48:1715-1718.
144. Matthay K, Seeger R, Haase G, et al: Treatment and outcome for stage III neuroblastoma based on prospective biologic staging [Abstract]. Med Pediatr Oncol 1994;23:173.
145. Paul SR, Tarbell NJ, Korf B, et al: Stage IV neuroblastoma in infants. Cancer 1991;67:1493-1497.
146. Matthay KK, Perez C, Seeger RC. et al: Successful treatment for stage III neuroblastoma based on prospective biologic staging. A Children's Cancer Group study. J Clin Oncol 1998;16: 1256-1264.
147. nd ed. Philadelphia:Lippincott; 1993. p. 739-767.
148. Matthay KK: Neuroblastoma. In Pochedly C (ed): "Neoplastic diseases of childhood". Chur, Switzerland: Harwood Academic; 1994. p. 735-778.
149. Cheung NK, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma [Review]. J Clin Oncol 1991;9:1050-1058.
150. Bernard JL, Philip T, Zucker JM, et al: Sequential cisplatin/VM-26 and vincristine/ cyclophosphamide/doxorubicin in metastatic neuroblastoma: An effective alternating non-cross-resistant regimen? J Clin Oncol 1987;5:1952-1959.
151. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12:2607-2613.
152. Seeger RC, Villablanca JG, Matthay KK, et al: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 1991; 366:527-533.
153. Graham-Pole J, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:152-158.
154. Philip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 1991;9:1037-1044.
155. Kushner BH, O'Reilly RJ, Mandell LR, et al: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991;9:274-279.
156. Dini G, Lanino E. Garaventa A, et al: Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol 1991;9: 962-969.
157. Handgretinger R, Anderson K, Lang P. et al: A phase 1 study of human/mouse chimeric antiganglioside GDS0024T2 S0000T antibody ch 14.18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-267.
158. Seeger RC, Siegel SE, Sidell N: Neuroblastoma: clinical perspectives, monoclonal antibodies, and retinoic acid. Ann Intern Med 1982;97:873-884.
159. Sidell N, Sarafian T, Kelly M, et al: Retinoic acid-induced differentiation of human neuroblastoma, a cell variant system showing to distinct responses. Exp Cell Biol 1986;54:287-300.
160. Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-193.
161. Finklestein JZ, Krailo MD, Lenarsky C, et al: 13-Cis-retinoic acid in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Children's Cancer Study Group. Med Pediatr Oncol 1992;20:307-311.
162. O'Donoghue JA, Wheldon TE, Babich JW, et al: Therappeutic implications of the uptake of radiolabeled MIBG for the treatment of neuroblastoma. Prog Clin Biol Res 1991;366:455-461.
163. Martelli H, Ricard M, Larroquet M, et al: Intraoperative localization of neuroblastoma in children with 1231-or 1251-radiolabeled metaiodobenzylguanidine. Surgery 1998;123:51-57.
164. Blatt J: Deferoxamine in children with recurrent neuroblastoma. Anticancer Res 1994:14;2109-2112.
165. Pierelli L, Iacone A, Quaglietta AM, et al: Haematopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study. Br J Haematol 1994;86:70-75.
166. Pratt CB, Stuart C, Santana VM, et al: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-543.